May 17, 2023
FTC uses novel antitrust theory against Amgen-Horizon merger
The agency’s objection is not the same as the usual policy concerns concerning mergers. Instead, the FTC worries that Amgen will offer rebates on two blockbuster Horizon drugs, used to treat thyroid eye disease and chronic refractory gout, to keep competitors out of the marketplace.
The U.S. Federal Trade Commission’s attempt, announced Tuesday, to block California-based Amgen Inc.’s acquisition of Horizon Therapeutics PLC rests on a novel antitrust theory to prevent large companies from bundling pharmaceutical drugs, legal experts say.
The agency’s objection is not the same as the usual policy concerns concerning mergers. Instead, the FTC worries that Amgen will offer rebates on two blockbuster Horizon drugs, used to...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In